Vapiprost

• CAT Number: I037964
• CAS Number: 85505-64-2
• Molecular Formula: C30H39NO4
• Molecular Weight: 477.64
• Purity: 98%
• Synonyms: Vapiprost; GR 32191; GR32191; GR-32191
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, (1R-(1alpha(Z),2beta,3beta,5alpha))-
• InChI: InChI=1S/C30H39NO4/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34)/b2-1-/t26-,27-,28-,30+/m0/s1
• InChIKey: GQGRDYWMOPRROR-XUSMOFMBSA-N
• SMILES: O=C(O)CC/C=CCC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCC3=CC=C(C4=CC=CC=C4)C=C3

Vapiprost(CAT: I037964) is a selective thromboxane A2 receptor (TP receptor) antagonist, widely studied for its role in modulating platelet aggregation and vascular tone. By inhibiting the action of thromboxane A2, it reduces vasoconstriction and platelet activation, making it a valuable tool in cardiovascular research. Vapiprost has been explored for its potential therapeutic applications in conditions such as thrombosis, atherosclerosis, and other cardiovascular disorders. Its mechanism of action provides insights into thromboxane-mediated pathways and supports the development of targeted treatments for cardiovascular health.